Gilead preclinical data

GILD presented data from two preclinical studies showing that injections of PMPA reduced levels of simian immunodeficiency virus by >99 percent and that PMPA topical gel provided 100 percent protection against vaginal transmission of SIV in primates.

As presented at the International Conference on Antiviral Research in Fukushima, Japan, daily injections of PMPA at 30 or 75 mg/kg/day were given for four weeks to 10 primates that had been infected with SIV for at least 19 weeks. After two or fewer weeks of treatment, PMPA reduced SIV levels by more than 99 percent versus no decrease in 2 untreated controls. Levels returned to baseline after treatment stopped. ...